Navigation Links
Leading Foundations to Form mHealth Alliance
Date:2/17/2009

Landmark study of mobile technology for global health also launched at GSM conference

Barcelona, Spain (Vocus) February 17, 2009 -- Three of the world's leading foundations involved in global health, technology and humanitarian assistance--the Rockefeller Foundation, the United Nations Foundation and The Vodafone Foundation--announced today at GSMA's Mobile World Congress an agreement to form the Mobile Health (mHealth) Alliance, a partnership that will work to maximize the impact of mobile health, especially in the developing world.



Terry Kramer, Vodafone Foundation Trustee said: "I believe it is critical for us to harness the benefits that mobile technology can bring to global healthcare, in both sociological and economic terms."

He continued: "When you consider that there are 2.2 billion mobile phones in the developing world, 305 million computers but only 11 million hospital beds you can instantly see how mobiles can create effective solutions to address healthcare challenges. Mobile technology is providing new hope in the provision and promotion of quality healthcare in a number of ways, such as accelerating the collection and storage of patient data, training rural professionals and personalizing the way patients receive medical treatment."

The formation of the Alliance resulted from a July 2008 Rockefeller Foundation-hosted conference on the future of mHealth, in which participants identified the need to increase collaboration in cross-sectoral and pan-regional partnerships to improve healthcare delivery in the developing world. Participants included representatives of Cisco, Google, Microsoft, Nokia, and Qualcomm, as well as the Earth Institute, MIT and th
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. BioTech Medical LLC Launches Leading Edge Powered by SDC Disinfectant Products
2. Inviro Medical Devices Is Awarded a Three Year Contract with Leading GPO Novation
3. Leading Healthcare Information Technology Company Adopts Brainware Enterprise Search and Intelligent Data Capture Solutions
4. Australias Leading Oncology Drug Compounder Chooses RIVA System
5. Leading UK Personal Trainer Challenges Standards of Service Within Fitness Industry to Get Results or Double Your Money Back Guarantee
6. Leading Supplemental Insurer Recommends Insurance Review Following Annual Benefit Enrollment Period
7. Leading Spring Water Brands From Nestle Waters Team Up With the American Heart Association START! Initiative
8. Univita Health Acquires Leading Web Services Company
9. Leading Food Allergy Research and Advocacy Groups Merge to Find Cure for Life-Threatening Childhood Disease
10. The Pancreatic Cancer Research and Education Act Addresses the Astounding Mortality of the Fourth Leading Cause of Cancer Death in the United States
11. Obama Reforms Could Spark New Healthcare Economy If Investors Increase Funding, Says Leading Healthcare Venture Firm
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Leading Foundations to Form mHealth Alliance 
Leading Foundations to Form mHealth Alliance
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10BioCryst Provides Update Regarding Peramivir for Influenza 5116 1BioCryst Provides Update Regarding Peramivir for Influenza 5116 2BioCryst Provides Update Regarding Peramivir for Influenza 5116 3BioCryst Provides Update Regarding Peramivir for Influenza 5116 4BioCryst Provides Update Regarding Peramivir for Influenza 5116 5Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3Doctor Visits Are Getting Short Shrift in Tight Economy 58589 1Doctor Visits Are Getting Short Shrift in Tight Economy 58589 2